Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.45 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154122 | 0.93 | PRMT6 (0.65) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154121 | 0.92 | PRMT6 (0.66) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154133 | 0.92 | PRMT6 (0.66) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154128 | 0.90 | PRMT6 (0.70) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL26452475 | 0.90 | PRMT6 (0.68) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154108 | 0.90 | PRMT6 (0.57) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154105 | 0.89 | PRMT6 (0.66) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154119 | 0.88 | PRMT6 (0.65) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154097 | 0.88 | PRMT6 (0.65) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16154102 | 0.86 | PRMT6 (0.62) | PRMT6ACHEPRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493501-B2 | Methyltransferase inhibitors for treating cancer | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140303106-A1 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303106-A1 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | GNMT, AS3MT, TPMT | PRMT6 13/4885ACHE 2989/4885PRKAB2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.